HIV reservoirs persistence despite antiretroviral therapy (ART) might be related to persistent immune activation and residual HIV production, requiring further therapeutic strategies. We demonstrated that the tyrosine kinase inhibitor (TKI) Dasatinib, used for chronic myeloid leukaemia, significantly blocks in vitro HIV1 production by 3.4 logs in HIV1-infected primary CD4+ T lymphocytes, by inhibiting cell activation and proliferation, without cell toxicity. This molecule deserves to be investigated further for HIV cure strategies to hinder persistent immune activation and residual viral production.
aUPMC Univ Paris 06, UMR-S945
bInserm, U945, Laboratory of Immunity and Infection, Paris, France
cUniversità Vita-Salute, San Raffaele Scientific Institute, Milan, Italy
dORVACS, Hospital Pitié-Salpêtrière
eUPMC Univ Paris 06, UMR-S943, Epidemiology, Therapeutics Strategies and Clinical Virology in HIV Infection, Paris, France
fInserm, U943, Epidemiology, Therapeutics Strategies and Clinical Virology in HIV Infection
gAP-HP, Hospital Pitié-Salpêtrière Hospital, Department of Virology
hAP-HP, Hospital Pitié-Salpêtrière Hospital, Department of Infectious and Tropical Diseases, Paris, France.
Correspondence to Brigitte Autran, Hôpital Pitie-Salpêtriere, Département d’immunologie, Paris, France. Tel: +33 142177930; fax: +33 142177490; e-mail: email@example.com